Guideline-directed medical treatment in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation.

Higuchi, Satoshi; Orban, Mathias; Adamo, Marianna; Giannini, Cristina; Melica, Bruno; Karam, Nicole; Praz, Fabien; Kalbacher, Daniel; Koell, Benedikt; Stolz, Lukas; Braun, Daniel; Näbauer, Michael; Wild, Mirjam; Doldi, Philipp; Neuss, Michael; Butter, Christian; Kassar, Mohammad; Ruf, Tobias; Petrescu, Aniela; Ludwig, Sebastian; ... (2022). Guideline-directed medical treatment in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation. European journal of heart failure, 24(11), pp. 2152-2161. Wiley 10.1002/ejhf.2613

[img]
Preview
Text
European_J_of_Heart_Fail_-_2022_-_Higuchi_-_Guideline_directed_medical_treatment_in_patients_undergoing_transcatheter.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

INTRODUCTION

Guideline-directed medical therapy (GDMT), based on the combination of beta blockers (BB), renin-angiotensin system inhibitors (RAS-I), and mineralocorticoid-receptor antagonists (MRA), is known to have a major impact on the outcome of the patients with heart failure with reduced ejection fraction (HFrEF). Although GDMT is recommended prior to M-TEER, not all patients tolerate it. We studied the association of GDMT prescription with survival in HFrEF patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) for secondary mitral regurgitation (SMR).

METHODS AND RESULTS

EuroSMR, a European multicenter registry, included SMR patients with left ventricular ejection fraction of less than fifty percent. The outcome was 2-year all-cause mortality. Of 1344 patients, BB, RAS-I, and MRA were prescribed in 1169 (87%), 1012 (75%), and 765 (57%) patients at the time of M-TEER, respectively. Triple GDMT prescription was associated with a lower 2-year all-cause mortality compared to non-triple GDMT (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.60-0.91). The association persisted in patients with glomerular filtration rate of <30ml/min, ischemic etiology, or right ventricular dysfunction. Further, a positive impact of triple GDMT prescription on survival was observed in patients with residual MR of ≥2+ (HR, 0.62; 95% CI, 0.44-0.86), but not in patients with residual MR of ≤1+ (HR, 0.83; 95% CI, 0.64-1.08).

CONCLUSION

Triple GDMT prescription is associated with higher 2-year survival after M-TEER in HFrEF patients with SMR. This association was consistent also in patients with major comorbidities or non-optimal results after M-TEER.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Praz, Fabien Daniel, Wild, Mirjam Gauri, Kassar, Mohammad, Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1879-0844

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

07 Jul 2022 09:34

Last Modified:

08 Jul 2023 00:25

Publisher DOI:

10.1002/ejhf.2613

PubMed ID:

35791663

Uncontrolled Keywords:

comorbidities guideline-directed medical therapy heart failure with reduced ejection fraction residual mitral regurgitation secondary mitral regurgitation transcatheter edge-to-edge-repair

BORIS DOI:

10.48350/171153

URI:

https://boris.unibe.ch/id/eprint/171153

Actions (login required)

Edit item Edit item
Provide Feedback